41 citations
,
April 1997 in “Fertility and sterility” Clomiphene citrate can reverse low hormone levels and symptoms in male runners with hypogonadotropic hypogonadism.
December 1998 in “Acta Crystallographica Section C-crystal Structure Communications” A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
February 2026 in “Journal of Dermatological Treatment” CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
CG2001 is safe and well-tolerated for treating hair loss in men.
August 2025 in “Skin Appendage Disorders” TCM is an effective and safe treatment for primary cicatricial alopecias.
1 citations
,
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes modest feminization in transgender female adolescents, and works better with added estrogens.
August 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
13 citations
,
July 2011 in “Journal of Dermatological Treatment” Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
2 citations
,
August 2017 in “Dermatologic Therapy” Topical cetirizine 1% increases hair density and may be a promising treatment for hair loss.
3 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” Low-dose Buserelin effectively reduces hirsutism with minimal side effects.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
January 1983 in “Elsevier eBooks” Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by affecting androgen functions and suppressing certain hormones.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” 1 citations
,
September 2023 in “Journal of the American Academy of Dermatology”
28 citations
,
September 2000 in “Journal of Medicinal Chemistry” Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
September 2023 in “Journal of the American Academy of Dermatology” 1 citations
,
November 2025 in “International Journal of Clinical Pharmacy” Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
3 citations
,
January 1996 in “Journal of Dermatological Treatment” The ointment is a safe, effective, and well-tolerated treatment for certain types of psoriasis.
12 citations
,
January 2019 in “Journal of Endocrinology” Baicalin may help reduce excessive male hormone levels in PCOS.
1 citations
,
January 2020 Cepharanthine shows promise as a potential lung cancer treatment by effectively killing cancer cells.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
1 citations
,
August 2024 in “Indian Dermatology Online Journal” Bicalutamide may effectively treat female pattern hair loss with minimal side effects.
7 citations
,
May 1983 in “Geburtshilfe und Frauenheilkunde” Intramuscular cyproterone acetate effectively treats hirsutism and improves skin conditions in women with hyperandrogenism.
12 citations
,
June 2001 in “Bioorganic & Medicinal Chemistry” Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.
7 citations
,
June 2017 in “The Journal of Dermatology”